Chugai Seiyaku Kabushiki Kaisha

Disease Adsorption System Technologies Co., Ltd.

Masato Higuchi

Yoshiro Niitsu

Junji Kato

Kazushi Shibuya

Kisaburo Deguchi

Kiyoshi Takatsuki

Makoto Kawakita

Takao Kimura

Masayoshi Takeuchi

Hiromitsu Matsuzaki

Provided are an adsorptive carbon which can effectively adsorb vivotoxins such as advanced glycation end products (AGEs), and an adsorbent containing the adsorptive carbon as an active ingredient. The adsorptive carbon according to the present invention has a total pore volume of 0.10 to 1.0 mL/g, an average pore diameter of 1.0 to 2.0 nm, and an absorbance of an infrared absorption band at 1650-1800 cmof no less than 0.005.

Adsorption carbon, and adsorbent

The present invention relates to a pharmaceutical composition for treatment of hepatic diseases which comprises erythropoietin as an active ingredient to reduce excess iron ions in the liver of a mammal with hepatic diseases, thus improving hepatic functions of said mammal. According to the present pharmaceutical composition with erythropoietin as an active ingredient, excess iron ions in the liver of a mammal with hepatic diseases can be decreased, so it is effective for treatment of chronic hepatitis, hepatic carcinoma, hepatocirrhosis etc. due to excess iron ions. Further, patient's anemia accompanying venesection can be prevented while excretion of excess iron ions can be promoted by using the venesection therapy in combination with the administration of said pharmaceutical composition. Furthermore, the pharmaceutical composition of the present invention is administered into a patient with chronic hepatitis C for whom IFN therapy is not effective to improve hepatic functions after which conventional IFN therapy is conducted whereby its therapeutic effect on said hepatitis can be expected.

Pharmaceutical composition for treatment of hepatic diseases

Thrombocytopoiesis stimulating factor

Growing community of inventors

Shizuoka, Japan

Masato Higuchi